US 12,168,048 B2
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
Patrick Soon-Shiong, Culver City, CA (US)
Assigned to NantCell, Inc., Culver City, CA (US)
Filed by NantCell, Inc., Culver City, CA (US)
Filed on May 16, 2024, as Appl. No. 18/666,594.
Application 18/666,594 is a division of application No. 18/510,369, filed on Nov. 15, 2023, granted, now 12,016,911.
Application 18/510,369 is a division of application No. 18/066,648, filed on Dec. 15, 2022, granted, now 11,857,612, issued on Jan. 2, 2024.
Application 17/747,253 is a division of application No. 16/932,331, filed on Jul. 17, 2020, granted, now 11,364,291, issued on Jun. 21, 2022.
Application 18/066,648 is a continuation of application No. 17/747,253, filed on May 18, 2022, granted, now 11,554,167, issued on Jan. 17, 2023.
Claims priority of provisional application 62/875,663, filed on Jul. 18, 2019.
Prior Publication US 2024/0293522 A1, Sep. 5, 2024
Int. Cl. A61K 39/04 (2006.01); A61K 35/15 (2015.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01)
CPC A61K 39/04 (2013.01) [A61K 35/15 (2013.01); A61K 39/001119 (2018.08); A61K 39/00114 (2018.08); A61K 39/39 (2013.01); A61K 39/4615 (2023.05); A61K 39/4622 (2023.05); A61K 39/4644 (2023.05); A61K 2039/515 (2013.01); A61K 2039/585 (2013.01)] 18 Claims
 
1. A method of treating cancer comprising:
a) administering to a subject having cancer an effective dose of Bacillus Calmette-Guerin (BCG) and an IL-15:IL-15Rα fusion protein complex;
b) isolating immune effector cells from a biological sample of the subject following step a, wherein the immune effector cells comprise antigen presenting cells, CD8+ T cells, and natural killer (NK) cells;
c) culturing the immune effector cells with a composition comprising the IL-15:IL-15Rα fusion protein complex; and
d) reinfusing the cultured immune effector cells into the subject, thereby treating the cancer.